Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2011 - 2026)

Acadia Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 0.42% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 2697.0% year-over-year to 0.42%; the TTM figure through Mar 2026 stood at 0.42% (down 2697.0% YoY), while the FY2025 annual figure was 2.67%, down 3758.0% from the prior year.
• Return on Capital Employed was 0.42% for Q1 2026 at Acadia Pharmaceuticals, down from 2.5% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 33.57% in Q4 2024 to a low of 47.62% in Q4 2022.
• Historically, Return on Capital Employed has averaged 4.51% across 5 years, with a median of 0.97% in 2024.
• The sharpest annual moves came in 2022 and 2024: Return on Capital Employed tumbled 4188 bps in 2022, then soared 5473 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 47.62% in 2022, then soared by 65 bps to 16.81% in 2023, then jumped by 300 bps to 33.57% in 2024, then tumbled by 93 bps to 2.5% in 2025, then sank by 83 bps to 0.42% in 2026.
• The last three Return on Capital Employed figures came in at 0.42% (Q1 2026), 2.5% (Q4 2025), and 26.14% (Q3 2025), per Business Quant data.